Treasurer of the State of North Carolina Acquires 115,290 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Treasurer of the State of North Carolina lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 53.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 330,391 shares of the company's stock after purchasing an additional 115,290 shares during the period. Treasurer of the State of North Carolina owned 0.07% of Elanco Animal Health worth $4,001,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ELAN. Wilmington Savings Fund Society FSB bought a new position in Elanco Animal Health in the 3rd quarter worth approximately $35,000. Jones Financial Companies Lllp grew its position in shares of Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares in the last quarter. MRP Capital Investments LLC bought a new position in Elanco Animal Health in the 4th quarter worth about $61,000. Finally, Blue Trust Inc. grew its holdings in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after buying an additional 1,894 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.89% of the company's stock.

Elanco Animal Health Trading Up 4.2 %

NYSE ELAN traded up $0.34 during trading on Friday, hitting $8.44. 5,406,589 shares of the company's stock traded hands, compared to its average volume of 4,915,626. The stock has a fifty day moving average of $10.26 and a two-hundred day moving average of $11.83. Elanco Animal Health Incorporated has a 12-month low of $8.02 and a 12-month high of $18.80. The firm has a market cap of $4.19 billion, a P/E ratio of 21.11, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.08 earnings per share. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELAN. Stifel Nicolaus decreased their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Piper Sandler dropped their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Barclays decreased their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $14.67.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.